Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc Stock Forecast & Price Prediction

Live Amphastar Pharmaceuticals Inc Stock (AMPH) Price
$51.91

2

Ratings

  • Buy 2
  • Hold 0
  • Sell 0
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$51.91

P/E Ratio

P/E Ratio not available for AMPH

Volume Traded Today

$420,176

Dividend

Dividends not available for AMPH

52 Week High/low

67.66/31.81

Amphastar Pharmaceuticals Inc Market Cap

$2.46B

🛑 Alert: These ten stocks could have higher potential than $AMPH 🛑

Before you buy AMPH you’ll want to see this list of ten stocks that have huge potential. Want to see if AMPH made the cut? Enter your email below

AMPH Summary

Based on ratings from 2 stock analysts, the Amphastar Pharmaceuticals Inc stock price is expected to increase by 21.36% in 12 months. This is calculated by using the average 12-month stock price forecast for Amphastar Pharmaceuticals Inc. The lowest target is $55.00 and the highest is $71.00. Please note analyst price targets are not guaranteed and could be missed completely.

AMPH Analyst Ratings

Amphastar Pharmaceuticals Inc has a total of 2 Wall St Analyst ratings. There are 2 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Amphastar Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

AMPH stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

david amsellem
Piper Sandler

Buy

$71.0

reiterated

Nov 30, 2023
nico chen
DBS

Buy

$55.0

maintained

Nov 24, 2023
jason gerberry
Bank of America Securities

Hold

$63.0

initiatedcoverage

Nov 17, 2023
serge belanger
Needham

Hold

None

maintained

Nov 9, 2023
glen santangelo
Jefferies

Buy

$70.0

initiatedcoverage

Jul 25, 2023
jacob hughes
Wells Fargo

Hold

None

rated

Jun 13, 2023
tim chiang
Capital One Financial

Buy

$44.0

initiatedcoverage

Jul 29, 2022
david steinberg
Jefferies

Buy

$33.0

maintained

Mar 10, 2022
elliot wilbur
Raymond James

Hold

None

maintained

Jul 1, 2021
gary nachman
BMO Capital

Hold

$21.0

maintained

May 11, 2020
alan carr
Needham

Buy

$24.0

reiterated

Mar 13, 2018

AMPH Company Information

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

AMPH
Amphastar Pharmaceuticals Inc (AMPH)

When did it IPO

2014

Staff Count

1,615

Country

United States

Sector/Industry

Healthcare/Drug Manufacturers—Specialty & Generic

CEO

Dr. Yongfeng Zhang Ph.D.

Market Cap

$2.46B

Amphastar Pharmaceuticals Inc(AMPH) Financial Data

In 2023, AMPH generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AMPH's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2019

N/A

Revenue From 2020

N/A

0.00 %
From Previous Year

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year
  • Revenue TTM $601.3M
  • Operating Margin TTM 0.40%
  • Gross profit TTM $248.9M
  • Return on assets TTM 0.10%
  • Return on equity TTM 0.25%
  • Profit margin 0.22499001%
  • Book value 12.43%
  • Market capitalisation $2.46B
  • Revenue for 2020 N/A
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • EPS this year 2.56
  • EPS next year N/A
... ...

Similar Stocks to Amphastar Pharmaceuticals Inc AMPH

🛑 Alert: These ten stocks could have higher potential than $AMPH 🛑

Before you buy AMPH you’ll want to see this list of ten stocks that have huge potential. Want to see if AMPH made the cut? Enter your email below

...

AMPH Frequently asked questions

The highest forecasted price for AMPH is $71.00 from david amsellem at Piper Sandler.

The lowest forecasted price for AMPH is $55.00 from nico chen from DBS

The AMPH analyst ratings consensus are 2 buy ratings, 0 hold ratings, and 0 sell ratings.